Search: WFRF:(Ledermann T.)
> (2024) >
Hidden in plain sig...
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer
-
- Roncolato, Felicia (author)
- Univ Sydney, Australia; Western Sydney Univ, Australia; Campbelltown Hosp, Australia
-
- King, Madeleine T. (author)
- Univ Sydney, Australia
-
- O'Connell, Rachel L. (author)
- Univ Sydney, Australia
-
show more...
-
- Lee, Yeh Chen (author)
- Univ Sydney, Australia; UNSW, Australia; Prince Wales & Royal Hosp Women, Australia
-
- Joly, Florence (author)
- Grp Investigateurs Nationaux Etud Canc Ovariens GI, France; Ctr Francois Baclesse, France
-
- Hilpert, Felix (author)
- Arbeitsgesmeinschaft Gynakol Onkol Studiengrp AGO, Germany; North Eastern German Soc Gynecol Oncol NOGGO, Germany; Krankenhaus Jerusalem, Germany
-
- Lanceley, Anne (author)
- UCL, England
-
- Yoshida, Yoshio (author)
- Univ Fukui, Japan
-
- Bryce, Jane (author)
- Multictr Italian Trials Ovarian Canc & Gynecol Mal, Italy; Ascens St John Clin Res Inst, OK USA; Ist Nazl Tumori IRCCS Fdn Pascale, Italy
-
- Donnellan, Paul (author)
- Galway Univ Hosp, Ireland
-
- Oza, Amit (author)
- Univ Toronto, Canada
-
- Åvall Lundqvist, Elisabeth (author)
- Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Nord Soc Gynaecol Oncol NSGO, Denmark; Karolinska Inst, Sweden
-
- Berek, Jonathan S. (author)
- Cooperat Gynecol Oncol Investigators COGI, CA USA; Stanford Univ, CA USA
-
- Ledermann, Jonathan A. (author)
- Canc Res UK, England; UCL Canc Trials Ctr, England
-
- Berton, Dominique (author)
- Grp Investigateurs Nationaux Etud Canc Ovariens GI, France; Inst Cancerol Ouest, France
-
- Sehouli, Jalid (author)
- Arbeitsgesmeinschaft Gynakol Onkol Studiengrp AGO, Germany; North Eastern German Soc Gynecol Oncol NOGGO, Germany; Charite Univ Med Berlin, Germany
-
- Kaminsky, Marie-Christine (author)
- Grp Investigateurs Nationaux Etud Canc Ovariens GI, France; Inst Cancerol Lorraine, France
-
- Stockler, Martin R. (author)
- Univ Sydney, Australia
-
- Friedlander, Michael (author)
- UNSW, Australia; Prince Wales & Royal Hosp Women, Australia
-
show less...
-
(creator_code:org_t)
- ACADEMIC PRESS INC ELSEVIER SCIENCE, 2024
- 2024
- English.
-
In: Gynecologic Oncology. - : ACADEMIC PRESS INC ELSEVIER SCIENCE. - 0090-8258 .- 1095-6859. ; 185, s. 128-137
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Objective. To describe the baseline symptom burden(SB) experienced by patients(pts) with recurrent ovarian cancer(ROC) prior and associations with progression free survival (PFS) and overall survival (OS). Methods. We analysed baseline SB reported by pts. with platinum resistant/refractory ROC (PRR-ROC) or potentially-platinum sensitive ROC receiving their third or greater line of chemotherapy (PPS-ROC >= 3) enrolled in the Gynecologic Cancer InterGroup - Symptom Benefit Study (GCIG-SBS) using the Measure of Ovarian Symptoms and Treatment concerns (MOST). The severity of baseline symptoms was correlated with PFS and OS. Results. The 948 pts. reported substantial baseline SB. Almost 80% reported mild to severe pain, and 75% abdominal symptoms. Shortness of breath was reported by 60% and 90% reported fatigue. About 50% reported moderate to severe anxiety, and 35% moderate to severe depression. Most (89%) reported 1 or more symptoms as moderate or severe, 59% scored 6 or more symptoms moderate or severe, and 46% scored 9 or more symptoms as moderate or severe. Higher SB was associated with significantly shortened PFS and OS; five symptoms had OS hazard ratios larger than 2 for both moderate and severe symptom cut-offs (trouble eating, vomiting, indigestion, loss of appetite, and nausea; p < 0.001). Conclusion. Pts with ROC reported high SB prior to starting palliative chemotherapy, similar among PRR-ROC and PPS-ROC >= 3. High SB was strongly associated with early progression and death. SB should be actively managed and used to stratify patients in clinical trials. Clinical trials should measure and report symptom burden and the impact of treatment on symptom control. (c) 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Roncolato, Felic ...
-
King, Madeleine ...
-
O'Connell, Rache ...
-
Lee, Yeh Chen
-
Joly, Florence
-
Hilpert, Felix
-
show more...
-
Lanceley, Anne
-
Yoshida, Yoshio
-
Bryce, Jane
-
Donnellan, Paul
-
Oza, Amit
-
Åvall Lundqvist, ...
-
Berek, Jonathan ...
-
Ledermann, Jonat ...
-
Berton, Dominiqu ...
-
Sehouli, Jalid
-
Kaminsky, Marie- ...
-
Stockler, Martin ...
-
Friedlander, Mic ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Gynecologic Onco ...
- By the university
-
Linköping University